News & Updates

Show Multimedia Only

Tenecteplase may improve stroke outcomes in patients with salvageable brain tissue

22 Feb 2026

In patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, administering intravenous tenecteplase between 4.5 and 24 h after stroke onset helps increase the chances of having an excellent functional outcome, although it contributes to an increased risk of symptomatic intracranial haemorrhage, according to a study.

Tenecteplase may improve stroke outcomes in patients with salvageable brain tissue

22 Feb 2026

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

20 Feb 2026 by

For patients with acute ischaemic stroke caused by a large-vessel occlusion, infusing alteplase into the artery after successful endovascular thrombectomy is beneficial, conferring functional gains and reducing persistent hypoperfusion, as shown in the phase III open-label CHOICE-2 trial.

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

20 Feb 2026

Cenobamate stands out for drug-resistant focal epilepsy in ASM showdown

19 Feb 2026 by

Cenobamate demonstrates superior effectiveness over other newer-generation antiseizure medications (ASMs) in the treatment of adult patients with drug-resistant focal epilepsy, according to a pooled analysis of four real-world studies.

Cenobamate stands out for drug-resistant focal epilepsy in ASM showdown

19 Feb 2026

Novel neuroprotectant loberamisal boosts functional recovery after stroke

19 Feb 2026 by

In patients with acute ischaemic stroke, administration of loberamisal, a novel neuroprotective agent, within 48 hours of symptom onset improves functional outcomes, according to the LAIS* trial presented at ISC 2026.

Novel neuroprotectant loberamisal boosts functional recovery after stroke

19 Feb 2026

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

18 Feb 2026 by

The oral factor XIa (FXIa) inhibitor asundexian scores high for secondary prevention in patients with non-cardioembolic stroke or high-risk transient ischaemic attack (TIA) who are receiving standard antiplatelet therapy, having met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trial.

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

18 Feb 2026

GLP-1 RAs may lower long-term mortality risk in AIS patients

16 Feb 2026 by

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appears to contribute to a long-term reduced risk of death in patients with acute ischaemic stroke (AIS), suggests a study. However, less than 1 percent of these individuals have been prescribed GLP-1 RAs upon discharge.

GLP-1 RAs may lower long-term mortality risk in AIS patients

16 Feb 2026

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026 by

Treatment with the short-acting glycoprotein IIb/IIIa inhibitor tirofiban after intravenous thrombolysis (IVT) results in significant improvements in 90-day functional outcomes among patients with acute ischaemic stroke, with no increase in haemorrhage or mortality, a study has shown.

Adjunct tirofiban improves functional outcomes in AIS

14 Feb 2026

Statin may be more harmful than beneficial in people with dementia

14 Feb 2026

For individuals with dementia, statin use does not appear to provide cardioprotective benefits but rather contributes to an increased risk of hospitalization due to cardiovascular or cerebrovascular events, according to a retrospective study.

Statin may be more harmful than beneficial in people with dementia

14 Feb 2026

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026 by

The use of intra-arterial (IA) alteplase following a successful endovascular thrombectomy (EVT) improves 90-day functional outcome in patients with large-vessel occlusion (LVO) acute ischaemic stroke compared with EVT-alone, according to the CHOICE 2* trial presented at ISC 2026.

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

13 Feb 2026

HDL-C a potential marker of functional outcome in ischaemic stroke

12 Feb 2026

Elevated concentrations of high-density lipoprotein cholesterol (HDL-C) are associated with favourable functional recovery in patients with ischaemic stroke, as suggested in a recent study.

HDL-C a potential marker of functional outcome in ischaemic stroke

12 Feb 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

Tenecteplase may improve stroke outcomes in patients with salvageable brain tissue

Tenecteplase may improve stroke outcomes in patients with salvageable brain tissue

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

Cenobamate stands out for drug-resistant focal epilepsy in ASM showdown

Cenobamate stands out for drug-resistant focal epilepsy in ASM showdown

Novel neuroprotectant loberamisal boosts functional recovery after stroke

Novel neuroprotectant loberamisal boosts functional recovery after stroke

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

GLP-1 RAs may lower long-term mortality risk in AIS patients

GLP-1 RAs may lower long-term mortality risk in AIS patients

Adjunct tirofiban improves functional outcomes in AIS

Adjunct tirofiban improves functional outcomes in AIS

Statin may be more harmful than beneficial in people with dementia

Statin may be more harmful than beneficial in people with dementia

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

HDL-C a potential marker of functional outcome in ischaemic stroke

HDL-C a potential marker of functional outcome in ischaemic stroke